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Abstract
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic 
antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and 
desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, 
doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 
genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical 
Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 
Genotypes and Dosing of Tricyclic Antidepressants.
Keywords
CYP2D6; CYP2C19; pharmacogenetics; tricyclic antidepressants; amitriptyline; clomipramine; 
desipramine; doxepin; imipramine; nortriptyline; and trimipramine
INTRODUCTION
Observed inter-individual differences in tricyclic antidepressant (TCA) pharmacokinetic 
parameters and treatment outcomes are associated with CYP2D6 and/or CYP2C19 genetic 
variation. The purpose of this guideline is to provide information to allow the interpretation 
of existing CYP2D6 and/or CYP2C19 genotyping results to guide TCA dosing and 
selection. Other clinical variables that may influence TCA therapy as well as genotyping 
cost-effectiveness are beyond the scope of this document. CPIC guidelines are periodically 
updated at https://cpicpgx.org/guidelines/ and http://www.pharmgkb.org.
FOCUSED LITERATURE REVIEW
A systematic literature review focused on CYP2D6 and CYP2C19 genetic variations and 
their relevance to gene-based dosing of TCAs was conducted (see Supplementary Data 
online). This guideline was developed based on interpretation of the literature by the authors 
and by experts in the field.
GENES: CYP2D6 AND CYP2C19
CYP2D6 background
The CYP2D6 gene is highly polymorphic. Over 100 known allelic variants and subvariants 
have been identified, and there are substantial ethnic differences in observed allele 
frequencies (CYP2D6 Allele Definition Table and CYP2D6 Frequency Table (1)). The most 
commonly reported alleles are categorized into functional groups as follows: normal 
function (e.g., CYP2D6*1 and *2), decreased function (e.g., CYP2D6*9, *10, and *41), and 
no function (e.g., CYP2D6*3-*6) (2, 3). Because CYP2D6 is subject to deletions or 
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duplications, many clinical laboratories also report copy number. Deletions are indicated by 
the CYP2D6*5 allele, and gene duplications are denoted by an “xN” following the allele 
(e.g., CYP2D6*1xN, where xN represents the number of CYP2D6 gene copies).
CYP2C19 background
Similar to CYP2D6, the CYP2C19 gene is highly polymorphic; over 35 known allelic 
variants and subvariants have been identified (3) (CYP2C19 Allele Definition Table (4)). 
Although there are ethnic differences in allele frequencies (CYP2C19 Frequency Table (4)), 
the majority of patients will carry a CYP2C19*1,*2,*3 or *17 allele (5). CYP2C19*1 is the 
wild-type allele encoding a fully functional enzyme. CYP2C19*2-*8 are no function alleles 
of which CYP2C19*2 is the most frequently observed, though CYP2C19*3 is more 
common among individuals of Asian ancestry (3, 5). The CYP2C19*17 allele, defined by a 
variant in the gene promoter region, causes enhanced gene transcription resulting in greater 
metabolic capacity (6) and is therefore classified as an increased function allele.
Genetic test interpretation
Clinical laboratories usually interrogate for the more frequently observed CYP2D6 and 
CYP2C19 genetic variants and translate the results into star-allele (*) nomenclature. Each 
star-allele, or haplotype, is defined by a specific combination of single-nucleotide 
polymorphisms and/or other genetic variants within the gene locus of either CYP2D6 or 
CYP2C19 (5). Genetic test results are reported as the summary of inherited maternal and 
paternal star-alleles referred to as a diplotype (e.g., CYP2D6*1/*2 and CYP2C19*1/*1). 
The more frequently observed alleles and their functional status can be found in the 
CYP2D6 (1) and CYP2C19 Allele Definition Tables (4).
Scoring systems have been developed in an attempt to provide a uniform approach to 
quantitate the predicted functional status of CYP2D6 alleles as follows: 1 for normal 
function, 0.5 for decreased function, and 0 for no function alleles (see Supplemental 
Material; CYP2D6 Allele Definition Table (1)) (2, 7). The activity value for each allele of 
the diplotype is totaled to provide a CYP2D6 activity score. If CYP2D6 gene duplications 
are detected, the activity value of the duplicated allele is multiplied by the number of 
duplications present before calculating the activity score (Table 1, Supplemental Tables S1 
and S2). See the Supplement for further explanation.
Patients with two normal function CYP2C19 alleles are categorized as normal metabolizers 
and individuals carrying one or two no function alleles are considered intermediate and poor 
metabolizers, respectively (Table 1). Limited data suggest that CYP2C19*17 may not 
compensate for no function alleles such as the CYP2C19*2 allele (8). Therefore, patients 
carrying the CYP2C19*17 increased function allele in combination with a no function allele 
are considered intermediate metabolizers. These phenotype assignments are analogous to the 
CPIC guideline for selective serotonin reuptake inhibitors (3). See Supplement for 
discussion regarding CYP2C19 rapid metabolizer phenotype.
Reference laboratories use varying methods to assign phenotypes. Before pharmacotherapy 
modifications are made based upon this guideline, it is advisable to determine a patient’s 
phenotype as described above.
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Available genetic test options
Commercially available genetic testing options change over time. Additional information 
about pharmacogenetic testing can be found at the Genetic Testing Registry website (http://
www.ncbi.nlm.nih.gov/gtr/).
Incidental findings
Independent of drug metabolism and response, there are currently no diseases or conditions 
that have been convincingly linked to variants in the CYP2D6 or CYP2C19 genes (5, 7).
DRUGS: AMITRIPTYLINE AND NORTRIPTYLINE
Background
Tricyclic antidepressants (TCAs) are mixed serotonin and norepinephrine reuptake inhibitors 
used to treat several disease states including depression, obsessive-compulsive disorder, and 
neuropathic pain in addition to migraine prophylaxis. The TCAs have similar but distinct 
chemical structures referred to as tertiary and secondary amines. The pharmacological 
properties of the tertiary and secondary amines differ, with tertiary amines having a more 
pronounced serotonergic effect and secondary amines having a greater noradrenergic effect 
(Supplemental Tables S3 and S4) (9, 10). The tertiary amines (e.g., amitriptyline) are mainly 
metabolized by CYP2C19 to desmethyl-metabolites (Figure 1), also referred to as secondary 
amines (e.g., nortriptyline). It should be noted that the desmethyl-metabolites nortriptyline 
as well as desipramine are pharmacologically active with antidepressant properties as well as 
with distinct clinical features that differ from the parent drugs amitriptyline and imipramine. 
Both the tertiary and secondary amines are metabolized by CYP2D6 to less active hydroxy-
metabolites (Figure 1, Supplemental Table S3). CYP2C19 impacts the ratio of tertiary to 
secondary amine plasma concentrations, but may have less influence on overall drug 
clearance than CYP2D6 (11). Although the total concentration of amitriptyline and 
nortriptyline may be unchanged for a CYP2C19 ultrarapid or poor metabolizer in certain 
instances, an imbalance between serotonergic and noradrenergic affect could influence 
clinical response or toxicities. There is limited evidence demonstrating that a serotonergic/
noradrenergic imbalance influences outcomes, thus contributing to the optional 
recommendations in Table 3. Serotonin reuptake inhibition is expected to be more 
pronounced in CYP2C19 poor metabolizers due to the decreased conversion of parent 
tertiary amines to their respective metabolites (10).
The use of TCAs to treat psychiatric disorders has declined in part due to the occurrence of 
undesirable side effects along with the growing availability of alternatives with more 
acceptable side effect profiles. Although TCAs are still used to treat depression (12), they 
are now more often used in the context of pain management (13, 14). Inter-individual 
differences in side effects and treatment response have been associated with variability of 
tricyclic plasma concentrations (15, 16). Patients may be predisposed to treatment failure or 
adverse effects due to genetic variation in CYP2D6 altering drug clearance or in CYP2C19 
altering the ratio of parent drug to metabolites. Common adverse effects include 
anticholinergic, central nervous system and cardiac effects. Tertiary and secondary amines 
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along with their metabolites each have unique side effect profiles as detailed in 
Supplemental Table S4.
Both amitriptyline and nortriptyline are used as representative TCAs for this guideline 
because the majority of pharmacogenomic studies have focused on these two drugs. 
However, the results of these studies may apply to other TCAs because these drugs have 
comparable pharmacokinetic properties (15, 17). TCAs are well absorbed from the 
gastrointestinal tract, and the average extent of first pass metabolism is approximately 50%, 
although the average first pass metabolism of doxepin may be closer to 70% (15). The 
clearance of TCAs is mostly a linear process, but saturation of the hydroxylation pathway 
may occur at higher plasma concentrations for certain TCAs including imipramine and 
desipramine (15, 18). Additionally, extrapolated dose adjustments based on metabolizer 
status are similar across the tricyclic class (17). Because some studies investigating the 
influence of CYP2D6 and/or CYP2C19 genotype/phenotype on the pharmacokinetics of 
TCAs used a single dose, it should be noted that in this guideline tricyclic metabolism was 
assumed to be similar after single or multiple dosing, and no differentiation was made 
between evidence from single dose studies or from multiple dose studies (16).
Linking genetic variability to variability in drug-related phenotypes
There is substantial evidence linking CYP2D6 and CYP2C19 genotypes to phenotypic 
variability in tricyclic side effects and pharmacokinetic profiles. Modifying 
pharmacotherapy for patients who have CYP2D6 or CYP2C19 genetic variants that affect 
drug efficacy and safety could potentially improve clinical outcomes, and reduce the failure 
rate of initial treatment. The application of a grading system to the evidence linking 
CYP2D6 and CYP2C19 genotypic variations to phenotypic variability in the response to 
amitriptyline or nortriptyline indicates a high quality of evidence in the majority of cases 
(Supplemental Tables S5–S7). This body of evidence, rather than randomized clinical trials, 
provides the basis for amitriptyline and nortriptyline dosing recommendations in Tables 2 
and 3, respectively. Optimal therapeutic plasma concentrations for the TCAs have been 
defined (19). CYP2D6 and CYP2C19 poor or ultrarapid metabolizers may have tricyclic 
plasma concentrations outside the recommended therapeutic range, thus increasing the risk 
of treatment failure or side effects (17, 20–22). TCA plasma concentrations have been 
shown to be predictive of toxicity and efficacy, with guidelines defining therapeutic ranges 
for TCAs (19). However, there are less data supporting a direct correlation between 
genotype and response when compared to the correlation between genotype and plasma 
concentrations. Some studies describe a relationship between genotype and response (23–
25) while other studies do not (26). Therefore, this guideline takes into consideration both 
clinical outcomes and observed tricyclic plasma concentrations based on genotype/
phenotype characteristics.
Therapeutic recommendations
CYP2D6 dosing recommendations—For neuropathic pain treatment, where lower 
initial doses of TCAs are used, gene-based dosing recommendations are found in the 
subsection Gene-based dosing recommendations for neuropathic pain treatment. Table 2 
summarizes the gene-based dosing recommendations for CYP2D6 and amitriptyline and 
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nortriptyline for situations in which a higher initial dose is warranted, such as depression 
treatment. The recommended starting dose of amitriptyline or nortriptyline does not need 
adjustment for those with genotypes predictive of CYP2D6 normal metabolism. A 25% 
reduction of the recommended dose may be considered for CYP2D6 intermediate 
metabolizers (27). The strength of this recommendation is classified as “moderate” because 
patients with a CYP2D6 activity score of 1.0 are inconsistently categorized as intermediate 
or normal metabolizers in the literature, making these studies difficult to evaluate.
CYP2D6 ultrarapid metabolizers have a higher probability of failing amitriptyline or 
nortriptyline pharmacotherapy due to subtherapeutic plasma concentrations, and alternate 
agents are preferred. There are documented cases of CYP2D6 ultrarapid metabolizers 
receiving large doses of nortriptyline in order to achieve therapeutic concentrations (22). 
However, very high plasma concentrations of the nortriptyline hydroxy-metabolite were 
present, which may increase the risk for cardiotoxicity. If a tricyclic is warranted, there are 
insufficient data in the literature to calculate a starting dose for a patient with CYP2D6 
ultrarapid metabolizer status, and therapeutic drug monitoring is strongly recommended. 
Adverse effects are more likely in CYP2D6 poor metabolizers due to elevated tricyclic 
plasma concentrations (28); therefore, alternate agents are preferred. If a tricyclic is 
warranted, consider a 50% reduction of the usual dose, and therapeutic drug monitoring is 
strongly recommended.
CYP2C19 dosing recommendations—Dosing recommendations for neuropathic pain 
treatment with amitriptyline are found in the subsection Gene-based dosing 
recommendations for neuropathic pain treatment. Table 3 summarizes the gene-based dosing 
recommendations for CYP2C19 and amitriptyline when higher initial starting doses are 
warranted. The usual starting dose of amitriptyline may be used in CYP2C19 normal and 
intermediate metabolizers. Although CYP2C19 intermediate metabolizers would be 
expected to have a modest increase in the ratio of amitriptyline to nortriptyline plasma 
concentrations, the evidence does not indicate that CYP2C19 intermediate metabolizers 
should receive an alternate dose.
Patients taking amitriptyline who are CYP2C19 rapid or ultrarapid metabolizers may be at 
risk for having low plasma concentrations and an imbalance between parent drug and 
metabolites causing treatment failure and/or adverse events. Although the CYP2C19*17 
allele did not alter the sum of amitriptyline plus nortriptyline plasma concentrations, it was 
associated with higher nortriptyline plasma concentrations, possibly increasing the risk of 
adverse events (8). For patients taking amitriptyline, extrapolated pharmacokinetic data 
suggest that CYP2C19 rapid or ultrarapid metabolizers may need a dose increase (17). Due 
to the need for further studies investigating the clinical importance of CYP2C19*17 
regarding tricyclic metabolism and the possibility of altered concentrations, we recommend 
to consider an alternative tricyclic or other drug not affected by CYP2C19. This 
recommendation is classified as optional due to limited available data. If amitriptyline is 
administered to a CYP2C19 rapid or ultrarapid metabolizer, therapeutic drug monitoring is 
recommended.
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CYP2C19 poor metabolizers are expected to have a greater ratio of amitriptyline to 
nortriptyline plasma concentrations (29). The elevated amitriptyline plasma concentrations 
may increase the chance of a patient experiencing side effects. Consider a 50% reduction of 
the usual amitriptyline starting dose along with therapeutic drug monitoring (17).
Other TCAs—Because the TCAs have comparable pharmacokinetic properties, it may be 
reasonable to extrapolate this guideline to other TCAs including clomipramine, desipramine, 
doxepin, imipramine, and trimipramine (Tables 2 and 3; Supplemental Tables S8–S16), with 
the acknowledgement that there are fewer data supporting dose adjustments for these drugs 
than for amitriptyline or nortriptyline.
CYP2D6 and CYP2C19 combined dosing recommendations—Although specific 
combinations of CYP2D6 and CYP2C19 alleles are likely to result in additive effects on the 
pharmacokinetic properties of TCAs, little information is available on how to adjust initial 
doses based on combined genotype information. Patients carrying at least one CYP2D6 no 
function allele and two CYP2C19 normal function alleles had an increased risk of 
experiencing side effects when administered amitriptyline, while patients with at least one 
CYP2C19 no function allele and two CYP2D6 normal function alleles had a lower risk of 
experiencing side effects (22, 30). Combinatorial gene-based recommendations are provided 
in Table 4. Therapeutic drug monitoring may be advised if a tricyclic is prescribed to a 
patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with 
CYP2C19 ultrarapid, rapid, intermediate or poor metabolism. There are sparse data in 
patients with a combinatorial CYP2C19 ultrarapid/rapid/intermediate/poor metabolizer 
phenotype and CYP2D6 ultrarapid/intermediate/poor phenotype. Because there are limited 
clinical or pharmacokinetic data regarding these combinatorial phenotypes, 
pharmacotherapy recommendations are classified as optional.
Gene-based dosing recommendations for neuropathic pain treatment—
Amitriptyline is often used at lower dosages (e.g., 0.1 mg/kg/day in pediatric patients; initial 
doses of 25 mg daily may be prescribed to adults) for treatment of neuropathic pain 
compared to treatment for depressive disorders (13, 14). Because of the lower dosage, it is 
less likely that CYP2D6 or CYP2C19 poor or intermediate metabolizers will experience 
adverse effects due to supratherapeutic plasma concentrations of amitriptyline (31). 
Therefore, we recommend no dose modifications for poor or intermediate metabolizers 
when prescribed amitriptyline at a lower dose for treatment of neuropathic pain, but these 
patients should be monitored closely for side effects. If larger doses of amitriptyline are 
warranted, we recommend following the gene-based dosing guidelines presented in Tables 
2–4.
There are limited data to support dose recommendations for CYP2C19*17 carriers who are 
prescribed amitriptyline at lower doses for neuropathic pain treatment. There are also little 
data describing the use of amitriptyline for neuropathic pain in CYP2D6 ultrarapid 
metabolizers. Based on predicted and observed pharmacokinetic data in those with 
depression, CYP2D6 ultrarapid metabolizers may be at an increased risk of failing 
amitriptyline therapy for neuropathic pain due to lower than expected drug concentrations, 
and thus alternative agents should be considered (32). Although there is sparse information 
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on how to adjust initial amitriptyline doses based on combined CYP2D6 and CYP2C19 
genetic results when treating neuropathic pain, caution should be used when patients have a 
combination of poor or ultrarapid phenotypes (e.g., a CYP2D6 poor metabolizer also having 
CYP2C19 ultrarapid or poor metabolism).
Pediatrics—There are scarce studies focusing solely on CYP2D6 or CYP2C19 genotype 
and association with pharmacokinetic parameters or treatment outcomes of TCAs in 
pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 
activity may be increased in children relative to adults (3). Although further genomic 
ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot 
be extrapolated to pediatric patients.
Other considerations
Consideration of drug interactions and patient characteristics—Patients treated 
for psychiatric disorders often require multiple medications, which can influence tricyclic 
plasma concentrations, side effects, and therapeutic failure (15). Recent data indicate that up 
to 20% of patients treated for depression may be converted to CYP2D6 poor metabolizer 
status (33). For example, patients taking amitriptyline in combination with a potent CYP2D6 
inhibitor, such as fluoxetine, may have dramatic increases in amitriptyline plasma 
concentrations (34). It has been suggested that patients taking strong CYP2D6 inhibitors 
should be treated similarly to CYP2D6 poor metabolizers (7). Additionally, patients with 
increased age, liver disease, and reduced renal function may require reduced doses of TCAs 
(15). Drug-drug interactions along with patient characteristics should be considered in 
addition to the gene-based dosing recommendations presented herein.
Minor metabolic pathways of TCAs—Other cytochrome P450 enzymes including 
CYP3A4 and CYP1A2 metabolize TCAs to a lesser extent (15, 31, 35, 36). There is 
currently no strong evidence supporting gene-based dosing recommendations for other CYP 
enzymes that metabolize TCAs.
Implementation of this guideline—The guideline supplement contains resources that 
can be used within electronic health records (EHRs) to assist clinicians in applying genetic 
information to patient care for the purpose of drug therapy optimization (see Resources to 
incorporate pharmacogenetics into an electronic health record with clinical decision support 
sections of supplement.).
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
For patients who have existing CYP2D6 and/or CYP2C19 genotyping test results, the 
potential benefit is identifying those patients who are at an elevated risk of experiencing side 
effects or therapeutic failure. For those patients, dose adjustments can be made or an 
alternative agent selected. A limitation inherent to most commercially available genotyping 
tests is that rare or de novo variants are not detected. Additionally, some alleles are not well 
characterized resulting in uncertainty when predicting the phenotype from some genetic test 
results. Genotyping is reliable when performed in qualified clinical laboratories, but as with 
any laboratory test, an error can occur. Any errors in genotyping or phenotype prediction, 
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along with the presence of a rare genomic variant not tested for, could potentially have 
lifelong implications for the patient’s drug therapy.
CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC 
TESTS
The application of genotype-based dosing is most appropriate when initiating therapy with a 
tricyclic. Obtaining a pharmacogenetic test after months of drug therapy may be less helpful 
in some instances, as the drug dose may have already been adjusted based on plasma 
concentrations, response, or side effects. Similar to all diagnostic tests, genetic tests are one 
of several pieces of clinical information that should be considered before initiating drug 
therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Major metabolic pathway of the tertiary amine amitriptyline and the secondary amine 
nortriptyline. For the structural representation the following 2D-images from the National 
Center for Biotechnology Information PubChem Compound Database are used: 
amitriptyline - CID=2160 (https://pubchem.ncbi.nlm.nih.gov/compound/2160); nortriptyline 
- CID=4543 (https://pubchem.ncbi.nlm.nih.gov/compound/4543); 10-hydroxyamitriptyline - 
CID=6420900 (https://pubchem.ncbi.nlm.nih.gov/compound/6420900); 10-
hydroxynortriptyline - CID=6420504 (https://pubchem.ncbi.nlm.nih.gov/compound/
6420504) (37). All entries were accessed Nov. 8, 2016.
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TABLE 1
ASSIGNMENT OF LIKELY PHENOTYPES BASED ON DIPLOTYPES
Assignment of CYP2D6 phenotypes
Likely phenotype Activity Score Genotypes Examples of diplotypes
Ultrarapid metabolizer (~1–
20% of patients)a
> 2.0 An individual carrying duplications of 
functional alleles
(*1/*1)xN, (*1/*2)xN, (*2/*2)xNb
Normal metabolizer (~72–
88% of patients) 1.0–2.0
c An individual carrying two normal 
function alleles or two decreased 
function alleles or one normal and no 
function allele or one normal function 
and decreased function allele or 
combinations of duplicated alleles that 
result in an activity score of 1.0–2.0.
*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, 
*1/*5, *1/*4
Intermediate metabolizer 
(~1–13% of patients)
0.5 An individual carrying one decreased 
function and one no function allele
*4/*41, *5/*9, *4/*10
Poor metabolizer (~1–10% of 
patients)
0 An individual carrying only no function 
alleles
*4/*4, (*4/*4)xN, *3/*4, *5/*5, *5/*6
Assignment of CYP2C19 phenotypes
Likely phenotype Genotypes Examples of diplotypes
Ultrarapid metabolizer (~2–5% of patients)a An individual carrying two increased function alleles *17/*17
Rapid Metabolizer (~2–30% of patients) An individual carrying one normal function allele and one 
increased function allele
*1/*17
Normal metabolizer (~35–50% of patients) An individual carrying two normal function alleles *1/*1
Intermediate metabolizer (~18–45% of patients) An individual carrying one normal function allele and one no 
function allele or one no function allele and one increased 
function allele
*1/*2, *1/*3, *2/*17d
Poor metabolizer (~2–15% of patients) An individual carrying two no function alleles *2/*2, *2/*3, *3/*3
aCYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 (4) and CYP2D6 
Frequency Tables (1) for population-specific allele and phenotype frequencies.
bWhere xN represents the number of CYP2D6 gene copies.
c
Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.
d
The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the 
CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele. See Supplemental Materials for 
a more comprehensive list of predicted metabolizer phenotypes.
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 c
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ce
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 d
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